SCHEMBL4969305

SCHEMBL4969305

COc1cc2ncnc(N3CCC(NC(=O)Nc4ccc(N5CCOCC5)cc4)CC3)c2cc1OC

nearest known ligand 0.61

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.61
PDGFRA P16234 4/20 0.56
KIT P10721 2/20 0.56
KDR P35968 1/20 0.56
PAK1 Q13153 1/20 0.55
ACHE P22303 5/20 0.55
BACE1 P56817 5/20 0.55
PDGFRB P09619 9/20 0.54
GAA P10253 1/20 0.54
ENPP1 P22413 1/20 0.54
FLT3 P36888 1/20 0.54
EPHX2 P34913 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4965465 0.95 PDE10A (0.57) PDE10APDGFRAKITKDRPAK1
SCHEMBL4969629 0.93 PDGFRA (0.60) PDGFRAKITKDRPAK1ACHE
SCHEMBL4966363 0.88 PDGFRA (0.56) PDE10APDGFRAKITKDRPAK1
SCHEMBL4966150 0.87 PDGFRB (0.70) PDGFRAKITKDRPAK1ACHE
SCHEMBL4967916 0.87 PDGFRA (0.57) PDE10APDGFRAKITKDRACHE
SCHEMBL4966832 0.86 PDGFRB (0.71) PDGFRAKITKDRPAK1PDGFRB
SCHEMBL4966896 0.86 PDGFRA (0.57) PDE10APDGFRAKITKDRPAK1
SCHEMBL4965855 0.84 PDGFRB (0.72) PDGFRAKITKDRPAK1PDGFRB
SCHEMBL2920768 0.84 PDGFRB (0.77) PDGFRAKITPDGFRBFLT3
SCHEMBL4974993 0.83 PDGFRA (0.64) PDE10APDGFRAKITKDRPAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899319-A2 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-19 EP disclosed
EP-1893206-A2 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-05 EP disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
WO-2006135649-A2 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
WO-2006135636-A2 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
US-20060281771-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281771-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS FLT3, CDC42BPG, PRKCQ PDE10A 4119/4885PDGFRA 460/4885KIT 197/4885
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS FLT3, BMX, ABL1 PDE10A 2325/4885PDGFRA 74/4885KIT 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.